Paul Hastings Advised Organovo Holdings On Sale Of FXR Program To Eli Lilly
Paul Hastings LLP advised Organovo Holdings, Inc. (Nasdaq: ONVO), a clinical-stage biotechnology company specializing in novel treatment approaches for inflammatory bowel disease, on the sale of its FXR program, including its lead asset FXR314, to Eli Lilly and Company (NYSE: LLY).
The Paul Hastings team was led by Jeff Hartlin (Chair, Palo Alto Corporate Department) and Samantha Eldredge (Partner), with key contributions from Lucas Rachuba (Partner), Todd Schneider (Partner), Maggie Chou (Associate), and Daniel Jun (Associate).